Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome

被引：0
作者：
Y. Degboé
M. Eischen
PA. Apoil
C. Mailhol
P. Dubreuil
O. Hermine
C. Paul
C. Bulai Livideanu
M. Laroche
机构：
[1] Toulouse University Hospital & Paul Sabatier University,Rheumatology Centre, Pierre Paul Riquet Hospital
[2] INSERM UMR 1043,Center for Pathophysiology of Toulouse Purpan
[3] CHU Purpan,Department of Immunology, Rangueil Hospital
[4] Toulouse University Hospital,Department of Pneumo
[5] Toulouse University Hospital,allergology, Larrey Hospital
[6] Aix Marseille University,Cancer Research Center of Marseille, INSERM , Institut Paoli Calmettes & CNRS, CEREMAST, Label Ligue Contre le Cancer
[7] Université Paris Descartes & Hôpital Necker Enfants Malades & Assistance Publique Hôpitaux de Paris,Department of Hematology, CEREMAST, Label Ligue Contre le Cancer
[8] Toulouse University Hospital & Paul Sabatier University,Department of Dermatology, Mastocytosis Expert Centre of Midi
来源：
Osteoporosis International | 2019年 / 30卷
关键词：
Fracture; Mast cell disorders; Mastocytosis; Osteoporosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1235 / 1241
页数：6
相关论文
共 231 条
[1]  
Barete S(2010)Systemic mastocytosis and bone involvement in a cohort of 75 patients Ann Rheum Dis 69 1838-1841
[2]  
Assous N(2017)Prevalence and risk factors for fragility fracture in systemic mastocytosis Bone 105 219-225
[3]  
de Gennes C(2009)Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients J Allergy Clin Immunol 124 514-521
[4]  
Grandpeix C(2011)Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis Bone 49 880-885
[5]  
Feger F(2016)Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis Osteoporos Int 27 2411-2421
[6]  
Palmerini F(2012)High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis Allergy 67 431-438
[7]  
Dubreuil P(2014)Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis J Allergy Clin Immunol 134 1413-1421
[8]  
Arock M(2001)Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 603-625
[9]  
Roux C(2017)Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts Blood 129 1420-1427
[10]  
Launay JM(2007)Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria Eur J Clin Investig 37 435-453
12345678910